VJToday

FDA approves oveporexton for the treatment of narcolepsy type 1 in adults

On August 5, 2026, the U.S. Food and Drug Administration (FDA) approved oveporexton for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The approval marks the introduction of the first and only approved orexin receptor 2 (OX2R) agonist and the first therapy designed to address the underlying orexin deficiency driving NT1 rather than treating individual symptoms alone.1

Unmet need in narcolepsy type 1

NT1 is a chronic neurological disorder of hypersomnolence characterized by excessive daytime sleepiness (EDS), cataplexy, disrupted nighttime sleep, and additional symptoms including cognitive impairment, sleep paralysis, and hallucinations. The condition results from the loss of orexin-producing neurons, leading to markedly reduced orexin signaling in the brain and cerebrospinal fluid.2

Current pharmacological approaches for NT1 primarily focus on symptom management, including improving wakefulness and reducing cataplexy. However, these treatments do not directly address the underlying pathophysiology of orexin deficiency. Oveporexton is an oral, selective OX2R agonist designed to restore orexin signaling in individuals with NT1. The approval of this agent represents a shift toward disease-directed therapy by restoring orexin pathway activity.1

Pivotal data: the FirstLight and RadiantLight Phase III trials

The FDA approval was supported by results from two global Phase III randomized, double-blind, placebo-controlled trials: FirstLight (TAK-861-3001; NCT06470828) and RadiantLight (TAK-861-3002; NCT06505031). These studies evaluated the efficacy, safety, and tolerability of twice-daily oral oveporexton over 12 weeks in adults with NT1.1,2

The FirstLight trial enrolled 168 participants randomized to receive oveporexton 2 mg twice daily, oveporexton 1 mg twice daily, or placebo. The RadiantLight trial enrolled 105 participants randomized to receive oveporexton 2 mg twice daily or placebo.2,3 Participants had confirmed NT1 based on International Classification of Sleep Disorders criteria, supported by objective sleep testing and evidence of orexin deficiency or HLA-DQB1*06:02 positivity.2

Both trials met their primary and key secondary endpoints, demonstrating statistically significant improvements with oveporexton compared with placebo (p<0.001) at week 12, regardless of dose. Improvements were observed in EDS and cataplexy, with outcomes approaching normative ranges. Oveporexton was generally well tolerated; the most frequently reported adverse events (AEs) were insomnia, urinary urgency, and urinary frequency. No serious treatment-related AEs were observed. 2

We recently spoke with Lucie Barateau, MD, PhD, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, France, who discussed the trials, highlighting:

“We had information about objective wakefulness on MWT and sleepiness on the Epworth Sleepiness Scale and also the cataplexy frequency, so these were the endpoints of the study. And the compound was safe and well tolerated, and it showed a lot of improvements in all the endpoints studied with a huge reduction in cataplexy frequency and a major improvement in wakefulness and subjective sleepiness in narcolepsy type 1 patients.”

Clinical implications

The approval of oveporexton represents a major advancement in the management of NT1 by introducing the first therapy targeting the underlying orexin deficiency responsible for the disease. Rather than focusing exclusively on individual symptoms such as EDS or cataplexy, oveporexton provides a mechanism-based approach intended to address the broad clinical spectrum of NT1.1,2

For healthcare professionals, this approval introduces a new therapeutic paradigm in NT1 care, with the potential to improve wakefulness, reduce cataplexy, enhance daily functioning, and address additional symptoms that contribute to the substantial burden of disease. As the first approved orexin-targeted therapy, oveporexton may redefine treatment discussions and expand options for adults living with NT1.1,3

Written by Hannah Elkheir

Reviewed by Natalie Markova

References

  1. Takeda. U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1. Available here. (Last accessed: 08/06/2026).
  2. Mignot E, Dauvilliers Y, Foldvary-Schaefer N, et al. Oveporexton (TAK-861) for the Treatment of Narcolepsy Type 1: Efficacy and Safety Results from Two Pivotal Phase 3 Trials. Chest. 2025;168(4).
  3. Takeda. New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1. Available here. (Last accessed: 08/06/2026).